Nicholas Haft

Nicholas Haft is the Managing Director at OMX Ventures, a biotechnology and life sciences venture capital firm based in Lincolnshire, United States. Previously, he served as the sole managing partner at Arcos Ventures, where he deployed more than $80 million in investment capital across over 20 early-stage bio-related companies. His extensive investment portfolio includes notable life sciences and biotechnology organizations such as Ginkgo Bioworks, 10X Genomics, Compass Pathways, Pendulum Therapeutics, and Finch Therapeutics. In addition to his investment roles, Haft co-founded Delix Therapeutics, a company developing treatments for psychiatric and neurological disorders, and acts as a Board Observer at Replay Bio. He earned a Bachelor of Science in Economics from the Wharton School at the University of Pennsylvania. His professional background remains focused on financing and building early-stage therapeutics and biotechnology enterprises targeting complex medical conditions.